Effects of renal impairment on the pharmacokinetics of sorafenib and its metabolites

934 Sorafenib is an oral multikinase inhibitor approved for renal cell carcinoma. We evaluated the pharmacokinetics (PK) of sorafenib in subjects with normal renal function compared to subjects with mild, moderate, or severe renal impairment. Subjects were classified into 4 groups based on renal function: normal function (Clcr>80 mL/min); mild (Clcr 50-80 mL/min), moderate (Clcr 30- Pri = Primary Analysis; Sec = Secondary Analysis; CV = Coefficient of Variation